Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02537-17
Abstract: ABSTRACT DS-2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection (CDI). The aim of this study was to assess the safety, tolerability, pharmacokinetics, and effects on the normal gastrointestinal… read more here.
Keywords: study assess; study; 2969b novel; novel gyrb ... See more keywords